Session Chair Profile
Biography
Dr. Sharon Benzeno is the Chief Commercial Officer, Immune Medicine and leads the Drug Discovery group of Adaptive Biotechnologies, a commercialstage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Before joining Adaptive in 2014, Sharon was Senior Director at Elsevier Inc., a healthcare informatics company. Prior to Elsevier, Sharon coled the oncology business unit at Capgemini SE, a consulting and technology services company. Sharon came to Elsevier from Capgemini, where she served in a variety of management roles at AstraZeneca plc. Sharon holds a PhD in Biomedical Sciences from New York University School of Medicine, an MBA in Finance and Leadership from New York University Stern School of Business and a BA in Biochemistry from New York University. Sharon completed a postdoctoral fellowship in cancer biology at the University of Pennsylvania Abramson Cancer Center.
Session Abstract – PMWC 2024 Silicon Valley
Track Chair: Sharon Benzeno, Adaptive Biotechnologies
- PMWC 2024 Award Ceremony
Pioneer Honoree: Stanley Riddell, Fred Hutchinson
Pioneer Honoree: George Coukos, Ludwig Cancer Center
- Discovery of Novel Targets in Cell Therapies in Oncology and Autoimmune Disorders (PANEL)
Chair: Harlan Robins, Adaptive Bio
- Stanley Riddell, Fred Hutchinson
- Allison Betof Warner, Stanford - Evolving Case Law and Practical Strategies for Immunotherapy Patents
- Janet Xiao, Morrison & Foerster LLP
- Scientific Advancements in Individualized Cell Therapeutics for Oncology( PANEL)
Chair: Sharon Benzeno, Adaptive Biotechnologies
- Ira Mellman, Genenetch
- George Coukos, Ludwig Institute for Cancer Research
- Bobert Meehan, Moderna - Supply Chain 2.0 Getting Cell Therapies to Patients (PANEL)
Chair: TBA
- Amanda Pace, Sonoma Bio - AI-Enhanced Approaches in Gene-Modified Cell Therapy Development
Chair: TBA
- Brian Weitzner, Outpace Bio
- Richard Bonneau, Prescient Design